The markets extended its losses during the midday with the Dow plunging 112 points to 17,625. Nasdaq plunged 43 points to 4,660.
On the upside
Shares of oil tanker operator Frontline (NYSE: FRO) continued soaring.
Celator Pharmaceuticals (Nasdaq: CPXX) published promising Phase 2 data for its CPX-351 in treating patients with first-relapse acute myeloid leukemia.
Advaxis (Nasdaq: ADXS) will begin four new clinical trials in 2015.
On the downside
Falling crude oil prices weighed down shares of Rex Energy (Nasdaq: REXX).
The China Association of Automobile Manufacturers reported that auto sales in China slowed sending shares of Bitauto (NYSE: BITA) plummeting.
In an update to its continuing Phase IIb study of eteplirsen in Duchenne muscular dystrophy patients, Sarepta Therapeutics (Nasdaq: SRPT) reported a continued decline in walking ability.
In the broad market, declining issues outpaced advancers by a margin of nearly 2 to 1 on the NYSE and by nearly 5 to 3 on Nasdaq. The broader S&P 500 fell 17 points to 2026. Bitcoin added $2 to $268.
